Effects of Daytime Eszopiclone Administration in Shift Workers

This study has been completed.
Sponsor:
Collaborators:
Sunovion
Massachusetts General Hospital
Information provided by:
Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00900159
First received: April 13, 2009
Last updated: July 11, 2011
Last verified: July 2011
  Purpose

The purpose of this study is to test the effects of eszopiclone on daytime sleep and overnight wakefulness in shift workers.


Condition Intervention
Shift-Work Sleep Disorder
Drug: eszopiclone
Drug: matching placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Daytime Eszopiclone Administration in Shift Workers on Overnight Wakefulness During a Subsequent Simulated Nightshift

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Nighttime wakefulness assessed by mean sleep latency across 4 Maintenance of Wakefulness Tests [ Time Frame: On each treatment, after an 8.5 hour daytime sleep period following at least 3 consecutive night shifts ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • EEG-recorded sleep efficiency [ Time Frame: On each treatment, during an 8.5-hr daytime sleep episode follwing at least 3 consecutive night shifts ] [ Designated as safety issue: No ]
  • Subjective sleepiness and performance [ Time Frame: On each treatment, after an 8.5-hr daytime sleep episode following at least 3 consecutive night shifts ] [ Designated as safety issue: No ]
  • Objective vigilance task performance [ Time Frame: On each treatment, after an 8.5 hour daytime sleep period following at least 3 consecutive night shifts ] [ Designated as safety issue: No ]
  • Sleep-dependent memory consolidation [ Time Frame: On each treatment, after an 8.5 hour daytime sleep period following at least 3 consecutive night shifts ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: May 2009
Study Completion Date: February 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: eszopiclone Drug: eszopiclone
3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Other Name: Lunesta
Placebo Comparator: matching placebo Drug: eszopiclone
3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Other Name: Lunesta
Drug: matching placebo
matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)

Detailed Description:

The current study seeks to extend the currently available treatments for SWSD by addressing the putative root cause of the problem—the inability of night-shift workers with or without SWSD— to obtain adequate daytime sleep in the face of the circadian drive for alertness that increases across the biological day. Even healthy, young subjects who are sleep-deprived overnight exhibit daytime sleep marked by frequent awakenings and low sleep efficiency, less slow-wave sleep, and altered sleep architecture, e.g. earlier predominance of REM sleep. Many night-workers routinely report 3-6 hours of habitual sleep duration for daytime sleep. Pharmacological interventions to decrease awakenings and improve total sleep time during daytime sleep could improve subsequent alertness during a night shift. Improving the wakefulness of night-shift workers over the nighttime could result in substantial benefits for the individual workers, improve workplace productivity and safety, and improve public health.

  Eligibility

Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 20-50 (men or women)
  • Current shift worker (for at least 3 months, at least 5 overnights/month and 3 consecutive)
  • A willingness and ability to comply with study procedures
  • If of child-bearing potential, using a medically-accepted method of birth control, including abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method, or intrauterine device [IUD]).

Exclusion Criteria:

  • Current diagnosis of DSM-IV Axis I disorder (other than insomnia)
  • Regular treatment (>1time/wk) with CNS-active medication within 1 month of first inpatient visit
  • Uncontrolled medical illness that would interfere with participation in the study
  • BMI>32 or < 19.8 kg/m2
  • Current symptoms or diagnosis of any moderate to severe sleep disorder other than SWSD
  • Periodic Leg Movement of Sleep Index (PLMSi)>20/hr of sleep or Respiratory Desaturation Index (RDI)>15 on polysomnography (PSG)
  • Current alcohol or drug dependence/abuse
  • Menopausal or peri-menopausal symptoms that disrupt sleep
  • Pregnant, lactating, or planning to become pregnant
  • Current smoking of more than 10 cigarettes per day
  • Current use of over the counter sleep aids such as Benadryl or melatonin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00900159

Locations
United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Sunovion
Massachusetts General Hospital
Investigators
Principal Investigator: Orfeu M Buxton, Ph.D. Brigham and Women's Hospital
  More Information

No publications provided

Responsible Party: Dr. Orfeu Buxton, Ph.D., Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00900159     History of Changes
Other Study ID Numbers: ESRC-977, 2009-P-000019
Study First Received: April 13, 2009
Last Updated: July 11, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
Shift-work
SWSD
eszopiclone
MWT
shiftworkers

Additional relevant MeSH terms:
Sleep Disorders
Parasomnias
Sleep Disorders, Circadian Rhythm
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Mental Disorders
Chronobiology Disorders
Dyssomnias
Occupational Diseases
Eszopiclone
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 23, 2014